AASK Cohort Study

高血压肾病通常进展。AASK（African American） 肾脏疾病和高血压的研究）队列研究是为了前瞻性地确定肾功能的过程 接受高血压肾病治疗的非裔美国人中肾脏疾病进展的危险因素 推荐的降压治疗。次要目的是确定心血管疾病的发生率 并评估其风险因素。 AASK队列研究是一项前瞻性、观察性研究，是AASK试验的扩展。AASK 一项试验检测了3种药物（雷米普利、美托洛尔）作为初始抗高血压治疗对肾功能的影响 和2级血压控制。在1,094名试验参与者中，约有650至700人 未达到终末期肾病（ESRD）的个体可能会参加队列研究。的危险因素 需要研究的变量包括环境、遗传、生理和社会经济变量。主要肾脏结局为 复合临床结局定义为血清肌酐加倍、ESRD或死亡。药物治疗 向所有参与者提供从血管紧张素转换酶抑制剂雷米普利开始的高血压。在这 时尚，该研究直接控制了肾脏疾病进展的两个主要决定因素（治疗 高血压和使用肾脏保护、抗高血压药物）。队列中的最短随访持续时间 研究时间为5年（包括AASK试验期在内，共9至12年）。 最终，来自AASK队列研究的数据应该会增强我们对风险因素的理解， 决定肾脏疾病进展的过程。这些结果最终可能会导致新的战略， 延缓或预防ESRD。

Hypertensive kidney disease commonly progresses. The primary objective of the AASK (African American Study of Kidney Disease and Hypertension) Cohort Study is to determine prospectively the course of kidney function and risk factors for kidney disease progression in African-Americans with hypertensive kidney disease who receive recommended antihypertensive therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK trial. The AASK trial tested the effects on kidney function of 3 medications used as initial antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control. Of the 1,094 trial participants, approximately 650 to 700 individuals who have not reached end stage renal disease (ESRD) will likely enroll in the Cohort Study. Risk factors to be studied include environmental, genetic, physiologic, and socio-economic variables. The primary renal outcome is a composite clinical outcome defined by doubling of serum creatinine, ESRD, or death. Medication treatment for hypertension, beginning with the angiotensin converting enzyme inhibitor ramipril, is offered to all participants. In this fashion, the study directly controls two of the major determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medication). The minimum duration of follow-up in the Cohort Study is 5 years (total of 9 to 12 years, including the period of the AASK trial). Ultimately, data from the AASK Cohort Study should enhance our understanding of the risk factors and processes that determine the progression of kidney disease. Such results might eventually lead to new strategies that delay or prevent ESRD.